

# Thyroid dysfunction in the elderly: quantifying the association between sub-clinical disease and (i) atrial fibrillation (and thus stroke) (ii) depression and (iii) cognitive dysfunction. A community based survey and clinical trial of thyroxine therapy

<b>Submission date</b> 12/09/2002	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
<b>Registration date</b> 12/09/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 14/09/2007	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Professor James V Parle

### Contact details

Department of Primary Care and General Practice  
University of Birmingham  
Edgbaston  
United Kingdom  
B15 2TT  
+44 (0)121 414 6420  
j.v.parle@bham.ac.uk

## Additional identifiers

EudraCT/CTIS number

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

226/657

## **Study information**

**Scientific Title**

**Acronym**

BETS (Birmingham Elderly Thyroid Study)

**Study objectives**

Not provided at time of registration

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Community based survey and randomised controlled trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

GP practice

**Study type(s)**

Screening

**Participant information sheet**

**Health condition(s) or problem(s) studied**

Thyroid dysfunction

**Interventions**

Intervention: Thyroxine replacement therapy. Dose to be increased by 25 mcg steps during 6 monthly period of monthly monitoring of thyroid function

Control: As for intervention group but placebo

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome measure**

Not provided at time of registration

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/01/2005

**Completion date**

01/01/2006

**Eligibility****Key inclusion criteria**

Phase 1: Aged 65+

Phase 2a: Patients identified in Phase 1 to be suffering from sub-clinical hyperthyroidism

Phase 2b: Patients identified in Phase 1 to be suffering from sub-clinical hypothyroidism

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

Not provided at time of registration

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/01/2005

**Date of final enrolment**

01/01/2006

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Department of Primary Care and General Practice**

Edgbaston

United Kingdom

B15 2TT

## **Sponsor information**

**Organisation**

The Health Foundation (UK)

**Sponsor details**

90 Long Acre

London

United Kingdom

WC2E 9RA

+44 (0)20 7257 8000

info@health.org.uk

**Sponsor type**

Charity

**Website**

<http://www.pppfoundation.org.uk/>

**ROR**

<https://ror.org/02bzj4420>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

The Health Foundation (UK)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results for community based survey:	01/12/2006		Yes	No